Prospective randomized comparative observation of single- versus split-dose lenograstim to enhance engraftment after autologous stem cell transplantation in patients with multiple myeloma or non-Hodgkin's lymphoma

Transfusion

Volumn 48, Issue 4, 2008, Pages 640-646

  Jang, Geundoo ^a   Ko, Ock Bae ^a   Kim, Shin ^a   Lee, Dae Ho ^a   Huh, Jooryung ^a   Suh, Cheolwon ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE COMPARISON; ENGRAFTMENT; FEMALE; HOSPITALIZATION; HUMAN; MALE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; AGED; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 41149144812     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01588.x     Document Type: Article

References (22)

1. Dunn C, Goa K. Lenograstim, an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings. Drugs 2000 59 : 681 717.
2. Smith T, Khatcheressian J, Lyman G, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006 24 : 3187 205.
3. Ozer H, Armitage J, Bennett L, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR for the American Society of Clinical Oncology Growth Factors Expert Panel. 2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 2000 18 : 3558 85.
4. Linch DC, Milligan DW, Winfield DA, Kelsey SM, Johnson SA, Littlewood TJ, Smith GM, Hutchinson RM, Goldstone AH, Fielding AK, Vaughan Hudson G. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997 99 : 933 8.
5. Bolwell B, Goormastic M, Dannley R, Andresen S, Overmoyer B, Mendez Z, Kalaycioglu M, DeMars D, Wise K, Pohlman B. G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 mg/ kg/day. Bone Marrow Transplant 1997 19 : 215 9.
6. Suh C, Kim HJ, Kim SH, Kim S, Lee SJ, Lee YS, Kim EK, Kim SB, Lee JS, Kim MW, Kim K, Yoon SS. Low-dose lenograstim to enhance engraftment after autologous stem cell transplantation: a prospective randomized evaluation of two different fixed doses. Transfusion 2004 44 : 533 8.
7. Hornedo J, Sola′ C, Solano C, Lopez JJ, Alonso S, Lluch A, Ojeda B, Garcia-Conde J, Cortes-Funes H. The role of granulocyte colony-stimulating factor (G-CSF) in the posttransplant period. Bone Marrow Transplant 2002 29 : 737 43.
8. Demirer T, Ayli M, Dagli M, Haznedar R, Genc Y, Fen T, Dincer S, Unal E, Gunel N, Seyrek E, Ustun T, Ustael N, Yildiz M, Sertkaya D, Ozetand G, Muftuoglu O. Influence of post-transplant recombinant human granulocyte colony-stimulating factor administration on peritransplant morbidity in patients undergoing autologous stem cell transplantation. Br J Haematol 2002 118 : 1104 11.
9. Arbona C, Prosper F, Benet I, Mena F, Solano C, Garcia-Conde J. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998 22 : 39 45.
10. Kröger N, Renges H, Kruger W, Gutensohn K, Loliger C, Carrero I, Cortes L, Zander AR. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation. Br J Haematol 2000 111 : 761 5.
11. Lee V, Li CK, Shing MM, Chik KW, Li K, Tsang KS, Zhao DC, Lai DH, Wong A, Yuen PM. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases. Bone Marrow Transplant 2000 25 : 931 5.
12. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Korbling M. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. Br J Haematol 2000 109 : 770 2.
13. Kröger N, Sonnenberg S, Cortes-Dericks L, Freiberger P, Mollnau H, Zander AR. Kinetics of G-CSF and CD34+ cell mobilization after once or twice daily stimulation with rHu granulocyte-stimulating factor (lenograstim) in healthy volunteers: an intraindividual crossover study. Transfusion 2004 44 : 104 10.
14. Carrion R, Serrano D, Gomez-Pineda A, Diez-Martin JL. A randomised study of 10 ug/kg/day (single dose) vs 2 × 5 ug/kg/day (split dose) G-CSF as stem cell mobilisation regimen in high-risk breast cancer patients. Bone Marrow Transplant 2003 32 : 563 7.
15. Kröger N, Zeller W, Hassan HT, Krüger W, Gutensohn K, Löliger C, Zander AR. Stem cell mobilization with G-CSF alone in breast cancer patients: higher progenitor cell yield by delivering divided doses (2 × 5 ug/kg) compared to a single dose (1 × 10 ug/kg). Bone Marrow Transplant 1999 23 : 125 9.
16. Kim S, Kim H, Park J, Lee J, Chi H-S, Park CJ, Huh J, Suh C. Prospective randomized comparative observation of single vs split-dose lenograstim to mobilize peripheral blood progenitor cells following chemotherapy in patients with multiple myeloma or non-Hodgkin's lymphoma. Ann Hematol 2005 84 : 742 7.
17. Suh C, Kim S, Kim S, Kim EK, Lee JL, Park KU, Park JS, Lee JS, Kim WK, Chi HS, Park CJ, Kim SW. Initiation of peripheral blood progenitor cell harvest based on peripheral blood hematopoietic progenitor cell counts enumerated by the Sysmex SE9000. Transfusion 2004 44 : 1762 8.
18. Lee J, Kim S, Kim S, Kim EK, Kim SB, Kang YK, Lee J, Kim MW, Park CJ, Chi HS, Huh J, Kim SH, Suh C. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005 35 : 449 54.
19. Lee JL, Kim SB, Lee GW, Ryu MH, Kim EK, Kim S, Kim WK, Lee JS, Kim SH, Suh CW. The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma. Yonsei Med J 2003 44 : 800 10.
20. Caballero M, Rubio V, Rifon J, Heras I, Garcia-Sanz R, Vazquez L, Vidriales B, del Canizo MC, Corral M, Gonzalez M, Leon A, Jean-Paul E, Rocha E, Moraleda JM, San Miguel JF. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 1997 20 : 451 8.
21. Martin-Murea S, Voso M, Hohaus S, Pforsich M, Fruehauf S, Goldschmidt H, Hegenbart U, Haas R. The dose of granulocyte colony-stimulating factor administered following cytotoxic chemotherapy is not related to the rebound level of circulating CD34+ haematopoietic progenitor cells during marrow recovery. Br J Haematol 1998 101 : 582 5.
22. Koenigsmann M, Jentsch-Ullrich K, Mohren M, Becker E, Heim M, Franke A. The role of diagnosis in patients failing peripheral blood progenitor cell mobilization. Transfusion 2004 44 : 777 84.